

Talk

Inhibitors and effectors of the glycosidases as therapeutic tools



Carmen Ortiz Mellet(1) y José Manuel García Fernández(2,*)

(1)Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, c/Profesor García Gozález 1, 41012 Sevilla.

(2)Instituto de Investigaciones Químicas, CSIC - Universidad de Sevilla, Avda. Américo Vespucio 49, 41092 Sevilla.

Keywords: glycomimetic; lysosomal storage disorders; pharmacological chaperone

ABSTRACT

Motivation: The lysosomal storage disorders (LSDs) conforms a group of over fifty monogenetic diseases characterized by the dysfunction of a lysosomal enzyme, frequently a glycosidase, and the subsequent accumulation of the corresponding substrate, which gives rise to several pathological manifestations. Individually they are rare diseases, but taken together they affect at 1 in 7,000 newborns. For some of these conditions enzyme replacement and/or substrate reduction therapeutic strategies (ERT and SRT, respectively) are available. Yet, most LSDs course with neurological deterioration and are refractory to ERT and SRT, remaining orphan diseases, since the respective active principles are unable to cross the blood brain barrier (BBB). Ironically, in most of the LSD patients the causative mutation leads to the expression of a mutated enzyme that retains catalytic activity, but it is unable to properly fold at the endoplasmic reticulum (ER) and undertake the secretory pathway to the lysosome. Small molecules capable of promoting the correct folding and restore trafficking, termed pharmacological chaperones (PCs), represents therefore a promising therapeutic option that is, in principle, better suited than ERT and SRT to target the neuronopathic forms.

Methods: We have conducted research aiming at developing active site-directed pharmacological chaperones for several LSDs based on glycomimetics (sugar lookalikes). The molecular design implies a nitrogen-in-the-ring cycle bearing a hydroxylation profile that matches that of the monosaccharide cleave off by the target enzyme (Sánchez-Fernández et al. 2016). Such compounds can sit at the active site of the glycosidase, behaving as competitive inhibitors, subsequently inducing proper folding and trafficking. The chaperones are further elaborated to make them dissociate from the chaperone:enzyme complex at the lysosome, allowing substrate processing (Mena-Barragán et al. 2015).

Results: PCs acting as glycosidase effectors in Gaucher, Fabry and GM1 gangliosidosis LSDs have been prepared based on the above concept.

Conclusions: The ability of the PCs to cross the (BBB) and revert the accumulation of the substrate in the brain tissue (Takai et al. 2013) supports the promise of pharmacological chaperone therapy for a range of LSDs with neurological implications.

REFERENCES

- Sánchez-Fernández, E.M. et al. (2016) Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. *Chem. Commun.*, 52, 5497-5515.
- Mena-Barragán, T. et al. (2015) pH-Responsive pharmacological chaperones for rescuing mutant glycosidases. *Angew. Chem. Int. Ed.*, 54, 11696-11700.
- Takai, T. et al. (2013) Bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. *Mol. Ther.*, 21, 526-532.